B
Bruce Morland
Researcher at Children's of Alabama
Publications - 99
Citations - 4135
Bruce Morland is an academic researcher from Children's of Alabama. The author has contributed to research in topics: Hepatoblastoma & Population. The author has an hindex of 32, co-authored 94 publications receiving 3268 citations. Previous affiliations of Bruce Morland include Boston Children's Hospital & University College Hospital.
Papers
More filters
Journal ArticleDOI
Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
Paolo G. Casali,Stefan S. Bielack,N. Abecassis,Hannu T. Aro,Sebastian Bauer,R. Biagini,Sylvie Bonvalot,Ioannis Boukovinas,Judith V.M.G. Bovée,Bernadette Brennan,Thomas Brodowicz,Javier Martin Broto,Laurence Brugières,Angela Buonadonna,E. de Álava,A. P. Dei Tos,X.G. del Muro,Palma Dileo,Catharina Dhooge,Mikael Eriksson,Franca Fagioli,Alexander Fedenko,Virginia Ferraresi,Andrea Ferrari,S. Ferrari,A.M. Frezza,Nathalie Gaspar,Silvia Gasperoni,Hans Gelderblom,Thierry Gil,Giovanni Grignani,Alessandro Gronchi,Rick L. Haas,B. Hassan,Stefanie Hecker-Nolting,Peter Hohenberger,Rolf D. Issels,Heikki Joensuu,Robin L. Jones,Ian Judson,Paul C Jutte,Suzanne E. J. Kaal,Leo Kager,Bernd Kasper,Katerina Kopeckova,D.A. Krakorova,Ruth Ladenstein,A. Le Cesne,Iwona Lugowska,Ofer Merimsky,Michael Montemurro,Bruce Morland,Maria Abbondanza Pantaleo,R. Piana,P. Picci,S. Piperno-Neumann,Antonio López Pousa,Peter Reichardt,M.H. Robinson,Piotr Rutkowski,Akmal Safwat,Patrick Schöffski,Stefan Sleijfer,Silvia Stacchiotti,Sandra J. Strauss,K. Sundby Hall,M. Unk,F. van Coevorden,W.T.A. van der Graaf,W.T.A. van der Graaf,W.T.A. van der Graaf,Jeremy Whelan,Eva Wardelmann,Olga Zaikova,Jean-Yves Blay +74 more
TL;DR: Primary bone tumours are rare, accounting for < 0.2% of malignant neoplasms registered in the EUROCARE (European Cancer Registry based study on survival and care of cancer patients) database, and different bone tumour subtypes have distinct patterns of incidence.
Journal ArticleDOI
DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome
Ingrid Slade,Chiara Bacchelli,Helen Davies,Anne Murray,Fatemeh Abbaszadeh,Sandra Hanks,Rita Barfoot,Amos Burke,Julia C. Chisholm,Martin Hewitt,Helen Jenkinson,Derek J. King,Bruce Morland,Barry Pizer,Katrina Prescott,Anand Saggar,Lucy Side,Heidi Traunecker,Sucheta Vaidya,Paul Ward,P. Andrew Futreal,Gordan M. Vujanic,Andrew G. Nicholson,Neil J. Sebire,Clare Turnbull,John R. Priest,Kathryn Pritchard-Jones,Richard S. Houlston,Charles A. Stiller,Michael R. Stratton,Jenny Douglas,Nazneen Rahman +31 more
TL;DR: Constitutional DICER1 haploinsufficiency predisposes to a broad range of tumours, making a substantial contribution to PPB, cystic nephroma and ovarian Sertoli–Leydig tumour, but a smaller contribution to other tumours.
Journal ArticleDOI
Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma
Giorgio Perilongo,Rudolf Maibach,Elisabeth Shafford,Laurence Brugières,Penelope Brock,Bruce Morland,Beatriz de Camargo,Jozsef Zsiros,Derek J. Roebuck,Arthur Zimmermann,Daniel C. Aronson,Margaret Childs,Eva Widing,Véronique Laithier,Jack Plaschkes,Jon Pritchard,Marcello Scopinaro,Gordon A. MacKinlay,Piotr Czauderna +18 more
TL;DR: Cisplatin monotherapy achieved similar rates of complete resection and survival among children with standard-risk hepatoblastoma and doxorubicin can be safely omitted from the treatment of standard- risk hepatoblowlastoma.
Journal ArticleDOI
Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study
Jozsef Zsiros,Laurence Brugières,Penelope Brock,Derek J. Roebuck,Rudolf Maibach,Arthur Zimmermann,Margaret Childs,Danièle Pariente,Véronique Laithier,Jean-Bernard Otte,Sophie Branchereau,Daniel C. Aronson,Arun Rangaswami,Milind Ronghe,Michela Casanova,Michael J. Sullivan,Bruce Morland,Piotr Czauderna,Giorgio Perilongo +18 more
TL;DR: The SIOPEL-4 treatment regimen is feasible and efficacious for complete remission at the end of treatment for patients with high-risk hepatoblastoma.
Journal ArticleDOI
UK guidelines for the management of bone sarcomas
Craig Gerrand,Nicholas A. Athanasou,Bernadette Brennan,Robert J. Grimer,Ian Judson,Bruce Morland,David Peake,Beatrice Seddon,Jeremy Whelan +8 more
TL;DR: This document is an update of the British Sarcoma Group guidelines and recommends that patients with clinico-radiological findings suggestive of a primary bone tumour at any site in the skeleton should be referred to a specialist centre and managed by a fully accredited bone sarcoma multidisciplinary team.